Review
Copyright ©The Author(s) 2015.
World J Hepatol. Jun 28, 2015; 7(12): 1632-1651
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1632
Table 4 Ongoing randomised phase II-III trials aimed at changing the standard of care in hepatocellular carcinoma management during the period 2012-2013[10]
IndicationRandomised studies
AdjuvantSorafenib vs placebo
Intermediate HCCChemoembolisation ± sorafenib
Chemoembolisation ± brivanib
Chemoembolisation ± everolimus
Advanced HCC
First lineSorafenib ± erlotinib
Sorafenib vs brivanib
Sorafenib vs sunitinib
Sorafenib vs linifanib
Sorafenib ± yttrium-90
Sorafenib ± doxorubicin
Second lineBrivanib vs placebo
Everolimus vs placebo
Ramucirmab vs placebo